Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-12-25 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
2024 年股权激励计划限制性股票授予结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the actual granting of restricted shares under a stock incentive plan, detailing the number of shares granted, recipients, vesting conditions, and performance criteria. It includes specifics about the stock source, grant price, and the impact on shareholding percentages. It also references an audit report related to the capital verification but does not contain full financial statements or comprehensive financial performance data. The document is a formal disclosure of a share-based compensation event and related shareholding changes, typical of a capital or financing update rather than a full annual or interim report. The document length is 4219 characters, which is relatively short and focused on a specific corporate action. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-12-25 Chinese
对外投资设立全资子公司并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Anhui Xuyi Pharmaceutical Co., Ltd. about the establishment of a wholly-owned subsidiary, Rizhao Xiaobei Pharmaceutical Co., Ltd., including details about the investment, registration, and business scope. It explicitly states that this investment does not constitute a major asset restructuring or related party transaction and does not require board or shareholder approval. The document is relatively short (1534 characters) and serves as a formal public announcement of a corporate action rather than a detailed financial report or regulatory filing. It does not contain financial statements, audit information, or detailed management discussion. Therefore, it fits best into the category of a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-12-18 Chinese
关于召开2024年第三次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2024 third extraordinary general meeting of shareholders (临时股东大会) for Anhui 峆一药业股份有限公司. It details the meeting date, voting methods (onsite and online), agenda items to be discussed, registration procedures, and other logistical information. It does not contain any financial statements, audit results, or detailed management discussion. The document is relatively short (2375 characters) and serves as an announcement for the meeting rather than the meeting materials or voting results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-12-10 Chinese
募集资金管理制度
Governance Information Classification · 95% confidence The document is titled as a "募集资金管理制度" which translates to "Fundraising Capital Management System" or "Management System for Raised Funds." It details the company's internal rules and procedures for managing and using raised funds, including storage, usage, supervision, and responsibilities. It references relevant laws and regulations, outlines approval processes, and describes internal controls and reporting requirements. The document is a formal policy or governance document rather than a financial report or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a certification. The content fits best under Governance Information (CGR), as it details the company's internal rules and governance practices related to capital management.
2024-12-10 Chinese
利润分配管理制度
Governance Information Classification · 95% confidence The document is titled as a "Profit Distribution Management System" of Anhui Xuyi Pharmaceutical Co., Ltd., detailing the company's policies, principles, procedures, and mechanisms for profit distribution to shareholders. It includes detailed governance on dividend distribution, cash dividends, stock dividends, decision-making processes, and supervisory mechanisms. The document is a formal policy or management system announcement rather than a financial report or earnings release. It is not an announcement of voting results, nor a proxy solicitation, nor a remuneration report. It is a governance-related document focusing on internal rules and procedures regarding profit distribution. Therefore, the most appropriate classification is Governance Information (CGR). The document length (4764 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2024-12-10 Chinese
第四届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 24th meeting of the 4th Board of Directors of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to related announcements on the stock exchange platform. The content focuses on board decisions regarding amendments to the company charter and governance rules, and the scheduling of a shareholders' meeting. There is no financial data, earnings information, or detailed report content. The document is an announcement of board/management decisions and changes, not a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1666 characters), consistent with an announcement rather than a full report.
2024-12-10 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.